TerminatedNot Applicable

Cardiomyopathy in Steroid-resistant Nephrotic Syndrome: Impact of Focal Segmental Glomerulosclerosis

Stopped: study stopped due to lack of activity

United States4 participantsStarted 2008-10

Plain-language summary

The objective of this study is as follows: * Perform genetic analysis to define the prevalence of each of the known gene mutations in an unselected cohort of patients with focal segmental glomerulosclerosis (FSGS) * Perform a comprehensive assessment of cardiovascular status to determine the incidence of any cardiac abnormalities in patients with FSGS * Determine if patients with mutations in specific proteins are more likely to have cardiovascular abnormalities * Initiate long-term follow up in all patients to determine whether cardiac prognosis is related to any specific genetic abnormality

Who can participate

Age range6 Months – 21 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 6 months - 21 years * SRNS, defined as failure to achieve remission in proteinuria after 4-6 weeks of daily steroid therapy in accord with ISKDC guidelines * GFR \> 30 ml/min/1.73 m\^2 * Renal disease diagnosed based on kidney biopsy Exclusion Criteria: * Secondary FSGS * Prior renal transplantation * Congenital extra-renal abnormalities * Significant structural cardiac abnormalities * pulmonary, hematologic, malignancy, or immune-related disease * inability to maintain adequate follow-up

What they're measuring

Presence or Absence of any of the podocin gene mutations

Timeframe: baseline

Trial details

NCT IDNCT00883636

SponsorNorthwell Health

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2011-08

View on ClinicalTrials.gov More Focal Segmental Glomerulosclerosis trials